Metabolic and Cardiovascular Effects of Dipeptidyl Peptidase-4 (DPP-4) or Sodium-glucose Co-transporter Type 2 (SGLT2) Inhibitors

• Status: Unknown status
• Trial end date: 2018-08-01
• Target enrollment: 0
• Participant gender: All

Summary

Inhibition of dipeptidyl peptidase-4 (DPP-4) or sodium-glucose co-transporter type 2 (SGLT2) has been proposed as a therapeutic target for type 2 diabetes. However, how DPP-4 inhibitors or SGLT2 inhibitors exert protective actions for diabetic complications in addition to their glucose-lowering effects remains unknown.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Kurume University
• Treatments: Glimepiride; Sodium-Glucose Transporter 2 Inhibitors

Criteria

Inclusion Criteria:

• Clinical diagnosis of type 2 diabetic patients

• Must be able to swallow tablets

• never received DPP-4 inhibitors or SGLT2 inhibitors

Exclusion Criteria:

• uncontrolled diabetes (fasting plasma glucose>200 mg/dL)

• receiving insulin therapy

• hepatic disorders (2.5 fold or greater increases in aspartate transaminase or alanine transaminase levels above the upper limits of normal)

• inflammatory disorders

• neoplastic disorders

• recent (<3months) acute coronary syndrome and stroke

• any acute infection